Replies to post #170598 on Biotech Values

[jbog]

If acquired Teva's identity would disappear. Teva's problem is simple, it is no longer a low cost producer of generic drugs.

There's a whole new class of top notch low cost companies that are hitting the world markets. They really haven't reached our shores yet but they will.